Clinical TrialJun 4, 2026, 07:01 AM
Axsome Therapeutics Presents New SYMBRAVO Migraine Data at AHS Meeting
AI Summary
Axsome Therapeutics announced the presentation of new SYMBRAVO® data at the American Headache Society (AHS) 68th Annual Scientific Meeting. The presentations highlight SYMBRAVO's efficacy and safety for the acute treatment of migraine. Key data includes post-hoc composite efficacy and return to function analysis from the MOMENTUM trial, comparative efficacy against gepants, and sustained pain relief from MOMENTUM and MOVEMENT trials.
Key Highlights
- Axsome Therapeutics presented new SYMBRAVO data at the AHS 68th Annual Scientific Meeting.
- Presentations included post-hoc composite efficacy and return to function analysis from MOMENTUM.
- Comparative efficacy of SYMBRAVO vs. gepants was shown in a network meta-analysis.
- Data on sustained pain relief and pain freedom from MOMENTUM and MOVEMENT trials were presented.
- Post-hoc composite efficacy and safety analysis from INTERCEPT and MOMENTUM trials was also shared.
Price Impact
More from AXSM